Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer

Journal of Radiation Research

Volumn 56, Issue 1, 2014, Pages 122-127

  Someya, Masanori ^a   Hori, Masakazu ^a   Tateoka, Kunihiko ^a   Nakata, Kensei ^a   Takagi, Masaru ^b   Saito, Masato ^a   Hirokawa, Naoki ^a   Hareyama, Masato ^c   Sakata, Koh Ichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO ION BEAM MEDICAL CENTER   (Japan)

^c Southern Tohoku General Hospital   (Japan)

Author keywords

3D CRT; DVH analysis; IMRT; late rectal toxicity; prostate cancer

Indexed keywords

GRAPHIC METHODS; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; RISK ASSESSMENT; UROLOGY;

3D-CRT; BLEEDINGS; DOSE-VOLUME HISTOGRAMS; DVH ANALYSE; IMRT; LATE RECTAL TOXICITIES; LOCALIZED PROSTATE CANCER; PROSTATE CANCERS; RADIATION TREATMENT PLANNING; RECTAL BLEEDING;

DISEASES;

AGED; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; GASTROINTESTINAL HEMORRHAGE; HUMAN; JAPAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIATION RESPONSE; RECTAL DISEASES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION PROTECTION; RADIOTHERAPY, CONFORMAL; RECTAL DISEASES; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84922419206     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rru080     Document Type: Article

References (17)

1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74
2. Dearnaly DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87
3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9
4. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53: 1097-105
5. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34
6. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70: 1124-9
7. Michalski JM, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76:S123-9
8. Gulliford SL, Foo K, Morgan RC, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010;76:747-54
9. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008;70:1130-7
10. National Comprehensive Cancer Network. Fort Washington, PA. http://www.nccn.org/(1 June 2014, date last accessed
11. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6
12. Pederson AW, Fricano J, Correa D, et al. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 2012;82:235-41
13. Tomita N, Soga N, Ogura Y, et al. Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer. J Radiat Res 2013;54:919-24
14. Mizowaki T, Hatano K, Hiraoka M. Surveillance on interfacility differences in dose-prescription policy of intensitymodulated radiation therapy plans for prostate cancer. J Radiat Res 2012;53:608-14
15. Takemoto S, Shibamoto Y, Ayakawa S, et al. Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer. Radiat Oncol 2012;7:87
16. Sato Y, Takayama T, Sagawa T, et al. Argon plasma coagulation treatment of hemorrhagic radiation proctopathy: the optimal settings for application and long-term outcome. Gastrointest Endosc 2011;73:543-9
17. Kerns SL, Stock RG, Stone NN, et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother Oncol 2013;107:372-6